变更与重新注册：无产品分组带来的连锁后果

I. Key takeaways

Cambodia does not allow product grouping for medical device registration. A chain rule follows: medical devices with different trademarks, different graphics, different sizes or different manufacturing sites must be registered separately, each with its own registration certificate.

This means change management in Cambodia cannot follow the “change notification” mindset — many situations that count as “a change under the same certificate” in other markets are, in Cambodia, a new registration.

GRZAN note: Cambodia’s product grouping policy is 0 (not allowed); 4 kinds of difference require separate registration (trademark, graphics, size, manufacturing site); transfer of a certificate after a change usually requires re-registration (practical interpretation).

II. Legal basis

III. Expert commentary

1. “No grouping” is the core variable in the Cambodia cost model. A product family of 20 SKUs represents close to 20 independent registrations in Cambodia, not 1. This must be made clear to decision-makers at project initiation, otherwise quotations will fall seriously short.

1. A manufacturing site change is a heavy event in Cambodia. Adding a second site or switching a contract manufacturer might be a “change of manufacturing address notification” elsewhere; in Cambodia it usually means a new registration. When planning capacity, factor in “new site = new registration cycle (12 to 18 months)”.

1. Certificate transfer likewise requires re-registration. Because the licence holder may be an overseas entity while the applicant must be a local company, a change of licence holder (for example through M&A or a brand transfer) usually requires re-registration in practice (practical interpretation). This directly affects transaction design — an acquirer cannot assume the certificate transfers with the equity.

IV. Practical recommendations

1. Estimate workload and budget by SKU count, not by product family, at project initiation. Treat every model as an independent registration unit.
2. Plan new manufacturing sites and new contract manufacturers as new registrations. Start 12 to 18 months ahead; do not wait until capacity is tight.
3. In M&A and brand transfer deals, make re-registration of the certificate a closing condition. Set out the transition arrangements and timetable for the certificate in the transaction documents.

V. Verification checklist

• □ Registration workload and budget estimated by SKU count
• □ Confirmed that different trademarks, graphics, sizes and manufacturing sites require separate registration
• □ New manufacturing sites planned on a new registration cycle (12 to 18 months)
• □ Re-registration requirement for certificate transfer built into transaction design
• □ Process for local representative changes and DDF notification mechanism in place
• □ Mechanism for synchronised labelling and instructions-for-use updates after changes in place

Regulatory information verified as of 29 October 2026.

In Southeast Asia, GRZAN’s core capabilities focus on three areas. First, tracking the legislative progress of dedicated medical device laws across member states: Singapore, Malaysia, Thailand, Indonesia, the Philippines and Vietnam have each established written device regulatory frameworks, while Cambodia still has no dedicated Medical Device Law; the current rules are pieced together from three layers — the registration-number legal basis provided by the 1996 Law on the Management of Pharmaceuticals and its 2007 Amendment Law, the classification and procedures provided by Prakas No. 1258 of 2012, and the technical framework provided by the ASEAN Medical Device Directive (AMDD) — so compliance certainty is markedly lower than in markets that have completed legislation. Second, local authorised representative services: GRZAN acts as the manufacturer’s statutory representative in Cambodia, handling registration submissions, regulatory communication and post-market reporting obligations, and helping resolve the practical issues of the Cambodian registered pharmacist and the Import-Export Pharmaceutical Company Licence. Third, quality system and testing support: establishing a quality management system conforming to ISO 13485 and organising the technical dossier under the ASEAN Common Submission Dossier Template (CSDT).

Business enquiries: info@grzanglobal.com